Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vical, Aventis, Merck and Co. Inc. deal

VICL received $1.6 million from the pharma companies'

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE